| __timestamp | Blueprint Medicines Corporation | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 31844000 | 14182353 |
| Thursday, January 1, 2015 | 48588000 | 15503028 |
| Friday, January 1, 2016 | 81131000 | 16183585 |
| Sunday, January 1, 2017 | 144687000 | 22382849 |
| Monday, January 1, 2018 | 243621000 | 33038206 |
| Tuesday, January 1, 2019 | 331450000 | 31777040 |
| Wednesday, January 1, 2020 | 326860000 | 41464134 |
| Friday, January 1, 2021 | 601033000 | 67178053 |
| Saturday, January 1, 2022 | 477419000 | 52531000 |
| Sunday, January 1, 2023 | 427720000 | 68914000 |
| Monday, January 1, 2024 | 341433000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Blueprint Medicines Corporation and Pharming Group N.V. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Blueprint Medicines increased its R&D expenses by over 1,200%, peaking in 2021 with a staggering 601 million dollars. In contrast, Pharming Group's R&D spending grew by approximately 385% during the same period, reaching its highest point in 2023 with nearly 69 million dollars. This significant disparity highlights Blueprint's aggressive strategy in pioneering new treatments, while Pharming maintains a more conservative approach. As the biotech landscape evolves, these spending patterns may influence their future market positions and innovation capabilities.
Eli Lilly and Company vs Blueprint Medicines Corporation: Strategic Focus on R&D Spending
Comparing Innovation Spending: Pfizer Inc. and Blueprint Medicines Corporation
GSK plc vs Pharming Group N.V.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for United Therapeutics Corporation and Blueprint Medicines Corporation
Intra-Cellular Therapies, Inc. vs Blueprint Medicines Corporation: Strategic Focus on R&D Spending
Comparing Innovation Spending: Summit Therapeutics Inc. and Blueprint Medicines Corporation
Blueprint Medicines Corporation or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Investment: Blueprint Medicines Corporation vs Viridian Therapeutics, Inc.
Pharming Group N.V. vs Opthea Limited: Strategic Focus on R&D Spending
Pharming Group N.V. or Verona Pharma plc: Who Invests More in Innovation?
Pharming Group N.V. or Protagonist Therapeutics, Inc.: Who Invests More in Innovation?
Pharming Group N.V. or Viridian Therapeutics, Inc.: Who Invests More in Innovation?